MedTrace Logo

IMU-838 and Oseltamivir in the Treatment of COVID-19

NCT04516915 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2023-08-22

No results posted yet for this study

Summary

To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) and standard care vs. Oseltamivir and standard care in adult subjects with coronavirus disease (COVID-19)

Conditions

  • Covid 19

Interventions

DRUG

IMU-838

IMU-838 twice daily at 22.5mg doses for 14 days

DRUG

Oseltamivir

Oseltamivir twice daily at 75mg doses for 14 days

Sponsors & Collaborators

  • Immunic AG

    collaborator INDUSTRY

  • University of Warwick

    collaborator OTHER

  • MODEPHARMA

    collaborator UNKNOWN

  • University Hospitals Coventry and Warwickshire NHS Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-15
Primary Completion
2022-05-20
Completion
2022-09-21

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04516915 on ClinicalTrials.gov